Diadexus receives FDA marketing clearance for PLAC (TM) test

July 20, 2003

SOUTH SAN FRANCISCO, Calif. - July 18, 2003 -- diaDexus, Inc., a privately held biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company marketing clearance for the PLAC™ test. This test is cleared as an aid in predicting an individual's risk for coronary heart disease (CHD), in conjunction with clinical evaluation and patient risk assessment.

The PLAC test measures the level of lipoprotein-associated phospholipase A2 (Lp-PLA2) in human blood. Lp-PLA2 is an enzyme that has been identified as a novel risk factor for coronary events.

As the leading cause of death in the United States, CHD accounts for more than one in every five deaths. Each year, more than 500,000 Americans die from CHD-associated events. Nearly half of all individuals who experience a coronary event do not exhibit traditional risk factors such as high blood pressure, elevated LDL cholesterol ("bad" cholesterol), smoking, diabetes mellitus, marked obesity or physical inactivity.

"The PLAC test is an important new tool which physicians may use to more accurately predict who is at risk for heart disease," said Christie Ballantyne, MD, director of the Center for Cardiovascular Disease Prevention at Baylor College of Medicine and the Methodist DeBakey Heart Center in Houston. "Somewhere between one-third and one-half of heart attacks occur in people considered to have normal LDL cholesterol. This test enables us to better determine who is at risk for CHD before an adverse event occurs, allowing both the individual and his or her physician to take proactive and preventative measures, such as lifestyle modification or therapeutic intervention."

Results from a study presented by Dr. Ballantyne at the American College of Cardiology Annual Meeting 2003 show that individuals with normal LDL, but elevated levels of Lp-PLA2, are twice as likely to experience a coronary event as those individuals with normal levels of both LDL and Lp-PLA2, independent of traditional risk factors and C-reactive protein (CRP). Additional results show that individuals with normal LDL, but high levels of both Lp-PLA2 and CRP, have the greatest risk of a coronary event.

"Receiving marketing clearance for the PLAC test represents an important milestone for diaDexus. There is significant market potential for a product that helps identify patients at risk for CHD who are not currently identified by traditional risk factors," said Patrick Plewman, chief executive officer of diaDexus.

Research is currently underway to evaluate the effects of statin therapy on Lp-PLA2 levels. In addition, GlaxoSmithKline is developing an inhibitor to Lp-PLA2 as a potential treatment for atherosclerosis. This inhibitor is currently in Phase II clinical trials.

Mayo Medical Laboratories offer testing for Lp-PLA2.

For more information on the PLAC test please visit www.plactest.com.

About diaDexus
diaDexus, Inc., a privately held biotechnology company, based in South San Francisco, Calif., is focused on the discovery, development and commercialization of novel, patent-protected diagnostic and therapeutic products with high clinical value. diaDexus utilizes genomics and bioinformatics to identify numerous disease-associated molecular targets. More information about the company may be found at www.diaDexus.com.

JMPR Associates, Inc.

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.